Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 9/20 | 0.54 |
| ▸ | NPC1 | O15118 | 7/20 | 0.54 |
| ▸ | RAB9A | P51151 | 7/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1020858 | 0.86 | EPHX1 (0.56) | EPHX2EPHX1NPC1RAB9AALDH1A1 | |
| SCHEMBL12954830 | 0.81 | EPHX1 (0.51) | EPHX2EPHX1NPC1RAB9AALDH1A1 | |
| SCHEMBL346223 | 0.81 | NPC1 (0.55) | EPHX2NPC1RAB9ASMN1; SMN2KMT2A | |
| Hydrochloric Acid SCHEMBL1019532 | 0.80 | EPHX1 (0.50) | EPHX2EPHX1NPC1RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL1019531 | 0.80 | EPHX1 (0.50) | EPHX2EPHX1NPC1RAB9AALDH1A1 | |
| SCHEMBL1019077 | 0.80 | SIGMAR1 (0.69) | EPHX2NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL12955131 | 0.79 | ABL1 (0.65) | EPHX2EPHX1NPC1RAB9AALDH1A1 | |
| SCHEMBL348757 | 0.79 | EPHX2 (0.58) | EPHX2EPHX1NPC1RAB9AALDH1A1 | |
| SCHEMBL5462623 | 0.78 | GAA (0.74) | EPHX2EPHX1NPC1RAB9AALDH1A1 | |
| SCHEMBL348179 | 0.76 | SIGMAR1 (0.58) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101848899-B | As the N-benzyl of LXR conditioning agent, N '-aryl carbonyl bridged piperazine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2016-03-02 | — | — | CN | disclosed |
| US-8314091-B2 | N-benzyl,N'-arylcarbonylpiperazine derivatives | MSD OSS B.V. (NL) | 2012-11-20 | — | — | US | disclosed |
| US-8314091-B2 | N-benzyl,N'-arylcarbonylpiperazine derivatives | MSD OSS B.V. (NL) | 2012-11-20 | — | — | US | disclosed |
| US-8314091-B2 | N-benzyl,N'-arylcarbonylpiperazine derivatives | MSD OSS B.V. (NL) | 2012-11-20 | — | — | US | disclosed |
| EP-2190827-B1 | N-BENZYL-N'-ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | ORGANON NV (NL) | 2011-01-12 | — | — | EP | disclosed |
| EP-2190827-B1 | N-BENZYL-N'-ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | ORGANON NV (NL) | 2011-01-12 | — | — | EP | disclosed |
| CN-101848899-A | N-benzyl, n' -arylcarbonylpiperazine derivatives as lxr modulators | ORGANON NV | 2010-09-29 | — | — | CN | disclosed |
| EP-2190827-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. Organon (NL) | 2010-06-02 | — | — | EP | disclosed |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | N.V. ORGANON AND PHARMACOPEIA, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | N.V. ORGANON AND PHARMACOPEIA, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | N.V. ORGANON AND PHARMACOPEIA, INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2009024550-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. ORGANON (NL) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009024550-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. ORGANON (NL) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | NPC1L1, NPC1, ABCB11 | EPHX2 1236/4885EPHX1 1175/4885NPC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.